What Are CJC-1295 and Ipamorelin?
CJC-1295: The Long-Acting GHRH Analog
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 29 amino acids. CJC-1295 with Drug Affinity Complex (DAC) binds to serum albumin, extending its half-life to approximately 6-8 days.
Teichman et al. (2006) demonstrated that subcutaneous CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults Teichman et al., 2006.
Ipamorelin: The Selective Growth Hormone Secretagogue
Ipamorelin is a pentapeptide that activates the growth hormone secretagogue receptor (GHSR). Raun et al. (1998) established it as a potent and selective GH secretagogue that did not release ACTH or cortisol significantly Raun et al., 1998.
The Synergy: Why Combine Them?
Yin et al. (2014) highlighted the synergistic effect when GHRH and GHSR agonists are co-administered Yin et al., 2014.
CJC-1295 acts as the “amplifier” — increasing somatotroph capacity via cAMP/PKA signaling.
Ipamorelin acts as the “trigger” — providing pulsatile GH release via PLC/IP3/DAG pathway.
Together, they produce GH elevations 2-3x greater than either peptide alone.
Clinical Evidence
Growth Hormone and IGF-1 Elevation
A single dose of CJC-1295 produced a 2-10 fold GH increase sustained for up to 6 days, with IGF-1 elevated for 9-11 days Teichman et al., 2006.
Safety Profile
Sigalos and Pastuszak (2018) highlighted that GH secretagogues show promise but need more long-term studies Sigalos & Pastuszak, 2018. A 2026 review noted limited evidence for clinical use in humans Mayfield et al., 2026.
Considering adding this to your protocol? Work with licensed providers who understand peptide therapy. Telegenix offers personalized protocols based on your bloodwork and goals. Schedule your free consultation today.
CJC-1295 + Ipamorelin vs. Other GH Therapies
| Feature | CJC-1295 + Ipamorelin | HGH (Somatropin) | MK-677 | Sermorelin |
|---|---|---|---|---|
| Mechanism | Dual GHRH + GHSR | Direct GH replacement | Oral GHSR agonist | GHRH analog |
| GH Pattern | Pulsatile (physiological) | Flat (supraphysiological) | Sustained | Pulsatile |
| IGF-1 Increase | 1.5-3x baseline | 2-5x baseline | 1.5-2x baseline | 1.2-2x baseline |
| Cortisol Impact | Minimal | None | Mild increase | None |
| Feedback Suppression | No | Yes | Minimal | No |
Dosing Protocols
| Protocol | CJC-1295 Dose | Ipamorelin Dose | Frequency | Duration |
|---|---|---|---|---|
| Anti-Aging | 100 mcg | 200 mcg | Once daily (before bed) | 12-16 weeks |
| Body Composition | 100 mcg | 300 mcg | 1-2x daily | 12-16 weeks |
| Recovery | 100 mcg | 200-300 mcg | 2x daily | 8-12 weeks |
| CJC-1295 DAC | 2 mg weekly | 200 mcg daily | See notes | 12-16 weeks |
Timing: Best on an empty stomach before bed. Avoid eating for 30-60 minutes after injection, as insulin blunts GH release.
What to Expect: Timeline
| Timeframe | Expected Effects |
|---|---|
| Week 1-2 | Improved sleep quality, vivid dreams |
| Week 3-4 | Increased energy, faster recovery |
| Week 6-8 | Skin quality improvements, body composition changes begin |
| Week 10-12 | Measurable fat loss, lean mass gains, improved IGF-1 on bloodwork |
| Week 12-16 | Full benefits realized; reassess with bloodwork |
Ready to start a personalized peptide protocol? The licensed providers at Telegenix specialize in peptide therapy and hormone optimization. Book a free consultation to get a protocol tailored to your bloodwork, goals, and biology.
Key Takeaways
The CJC-1295 + Ipamorelin stack represents the current gold standard in peptide-based growth hormone optimization. The clinical evidence supports its safety and efficacy for GH and IGF-1 elevation, though long-term human data remains limited.
Related Comparison: Tesamorelin vs Ipamorelin: GH Peptide Comparison [blocked]
Related Comparison: NAD+ vs NMN: Which Longevity Supplement? [blocked]
Related Comparison: Sermorelin vs CJC-1295: Complete Comparison [blocked]
References
- Teichman SL, et al. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed
- Raun K, et al. Eur J Endocrinol. 1998;139(5):552-61. PubMed
- Yin Y, et al. Int J Mol Sci. 2014;15(3):4837-55. PMC
- Sigalos JT, Pastuszak AW. Sex Med Rev. 2018;6(1):45-53. PMC
- Mayfield CK, et al. Am J Sports Med. 2026;54(1):223-229. Link
Explore Related Peptides on OnlinePeptideDoctor.com
- The Wolverine Stack: BPC-157 + TB-500 [blocked] — Add tissue repair to your GH protocol
- DSIP: Deep Sleep Peptide [blocked] — Optimize sleep for maximum GH release
- NAD+ Therapy: Cellular Energy [blocked] — Enhance metabolic function alongside GH
- BPC-157 Arginine Salt [blocked] — Gut health and recovery support
- Browse All Peptide Articles [blocked] — 80+ research-backed articles
Disclaimer: This article is for educational and informational purposes only. It is not medical advice. CJC-1295 and Ipamorelin are research peptides not FDA-approved for clinical use.
Related Reading
Explore more in-depth guides on related topics:
- CJC-1295: What the Science Actually Says — A PubMed-Backed Review [blocked]
- CJC-1295 and Ipamorelin: The Growth Hormone Stack Explained [blocked]
- Ipamorelin: What the Science Actually Says — A PubMed-Backed Review [blocked]
- Sermorelin: What the Science Actually Says — A PubMed-Backed Review [blocked]
- MK-677 (Ibutamoren): What the Science Actually Says — A PubMed-Backed Review [blocked]
For a comprehensive overview, see our Complete Guide to Peptide Therapy [blocked].
